<DOC>
	<DOC>NCT02337569</DOC>
	<brief_summary>The objective of this study is to evaluate efficacy and safety of NPC-02 in patients with Zinc Deficiency.</brief_summary>
	<brief_title>A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency</brief_title>
	<detailed_description />
	<criteria>The serum zinc concentrations are under the normal level before registration 1. Heavy hepatitis 2. Malignant tumor 3. Severe heart disease, hematological disorder, kidney disease and pancreatic disease, etc. 4. The serum albumin under 2.8 g/dL 5. Patient of allergy and hyperesthesia to zinc containing medicine manufacturing (including supplement) 6. Patient who was taking a medicine including the zinc (including supplement) within 12 weeks before registration 7. Pregnant, suspected pregnant, lactating, patients who wish to have a child 8. Patient who participated in other clinical trials within 12 weeks before registration 9. Unsuitable as a target of this clinical trial judged by doctor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>